BCAL Diagnostics Ltd (ASX: BDX) Share Price and News

Mr Darling brings commercial experience from the life sciences and biotechnology sectors, including experience in the commercialisation of diagnostic products across global markets, with operations in New Zealand, Australia, Singapore and the USA. Prior to this, Mr Darling held senior management roles within the corporate sector. Mr Darling has more than three decades of experience in the development and commercialisation of life sciences and biotechnology products. Mr Darling has focused on the growth and international commercialisation of start-up and emerging companies within the life sciences and biotechnology sectors. He also has governance and executive management experience and has served as a director of businesses operating in New Zealand, Australia, Singapore and the USA. He is also a director of a number of private businesses and organisations.

Ms Shaw has experience in the healthcare sector in Australia and internationally. Following her arrival in Australia, she worked in private hospitals before establishing a healthcare consulting business. Ms Shaw was involved in the development of an ophthalmic practice consolidation model and has been a member of a number of private healthcare boards involved with specialist consolidation, including cardiology, orthopaedics and women's health. She has also worked with private equity firms on local and international healthcare transactions. Ms Shaw was also involved in the establishment of healthcare businesses and diagnostic ventures.

Mr McConnell's experience covers business strategy, investor relations, capital raising and innovation. He has worked with technology businesses in Australia and overseas. He has been involved in the establishment and development of software and technology businesses and advises technology start-up companies.

Dr Hurrell has developed products and services in life sciences and diagnostics over a career spanning more than 35 years. He has worked with start-up and early-stage companies, including life science businesses based on university-developed technologies. He has held managerial and executive roles within the clinical laboratory and diagnostics sectors, with experience in product development, business development and commercialisation activities. Other previous roles have included responsibilities across research and development, chronic disease management, international sales and business operations within organisations focused on diagnostics, healthcare and molecular testing. His experience spans North America, Asia Pacific and other international markets.

Mr Trollip has over 30 years of commercial, corporate, governance, legal and transactional experience. He has held board roles across a range of organisations. Mr Trollip has a keen interest in the not-for-profit sector and is involved with various not-for-profit organisations. He is the chair of the Risk Management Committee.

-

-

-

-